Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments

Eur J Clin Pharmacol. 2018 Mar;74(3):323-330. doi: 10.1007/s00228-017-2374-4. Epub 2017 Nov 17.

Abstract

Purpose: The development of non-vitamin K-dependent oral anticoagulants (NOACs) is a new alternative to treatment with warfarin. The purpose of this study was to explore drug prescription decisions of NOACs or warfarin from hospital physicians in cardiovascular departments.

Methods: A qualitative study with focus group interviews was conducted in three different hospitals. The interview guide explored the background of prescribing anticoagulants (warfarin, dabigatran, rivaroxaban, and apixaban) and experiences with effect and side-effects they had observed in patients.

Results: The systematic text condensation eluded four main themes: when to prescribe NOACs, concern about side-effects, pharmaceutical properties and patient adherence, and prescribing policy and intra-professional communication. All available anticoagulants were prescribed. However, no specific NOAC was preferred. Factors perceived as contraindications for NOACs varied among the doctors. Most had observed side-effects of NOACs; however, these rarely influenced prescribing decisions due to small differences in safety profiles. Few drug-drug interactions and fixed daily doses made NOACs easy to prescribe; but some doctors had experienced lack of drug effect for some patients. Non-adherence with NOACs was harder to spot. Some different prescribing cultures had evolved between the different hospitals and between general practitioners.

Conclusion: The hospital physicians chose anticoagulants based on patient conditions as renal function, bleeding risks, and drug interactions being the most common taken into account. They could not say which NOAC was best, and wish that future studies could compare the different NOACs, and not just compare with warfarin.

Keywords: Adverse reactions; Anticoagulants; Drug prescriptions; Drug-related side-effects; Hospital physicians; NOAC; Warfarin.

Publication types

  • Comparative Study
  • Multicenter Study

MeSH terms

  • Administration, Oral
  • Anticoagulants / administration & dosage
  • Anticoagulants / adverse effects
  • Anticoagulants / therapeutic use*
  • Antithrombins / administration & dosage
  • Antithrombins / adverse effects
  • Antithrombins / therapeutic use*
  • Cardiovascular Diseases / drug therapy
  • Cardiovascular Diseases / prevention & control
  • Clinical Decision-Making
  • Dabigatran / administration & dosage
  • Dabigatran / adverse effects
  • Dabigatran / therapeutic use*
  • Drug Monitoring
  • Drug Resistance
  • Factor Xa Inhibitors / administration & dosage
  • Factor Xa Inhibitors / adverse effects
  • Factor Xa Inhibitors / therapeutic use*
  • Focus Groups
  • General Practitioners
  • Hemorrhage / chemically induced
  • Hemorrhage / epidemiology
  • Hemorrhage / prevention & control
  • Humans
  • Medical Staff, Hospital
  • Medication Adherence
  • Norway / epidemiology
  • Practice Patterns, Physicians'*
  • Pyrazoles / administration & dosage
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use
  • Pyridones / administration & dosage
  • Pyridones / adverse effects
  • Pyridones / therapeutic use
  • Qualitative Research
  • Risk
  • Rivaroxaban / administration & dosage
  • Rivaroxaban / adverse effects
  • Rivaroxaban / therapeutic use*
  • Warfarin / adverse effects
  • Warfarin / therapeutic use*

Substances

  • Anticoagulants
  • Antithrombins
  • Factor Xa Inhibitors
  • Pyrazoles
  • Pyridones
  • apixaban
  • Warfarin
  • Rivaroxaban
  • Dabigatran